Daily Respiratory Research Analysis
Three impactful respiratory studies stood out: an AI-powered spatial cell phenomics framework markedly improved risk stratification in non-small cell lung cancer; a mechanistic COPD study identified a circRNA (circFCHO2)–PTBP1–GRN–NF-κB axis driving airway remodeling and showed therapeutic reversal in vivo; and a large prospective cohort with deep-learning HRCT quantification clarified progression phenotypes and risk factors in idiopathic inflammatory myopathy–associated ILD.
Summary
Three impactful respiratory studies stood out: an AI-powered spatial cell phenomics framework markedly improved risk stratification in non-small cell lung cancer; a mechanistic COPD study identified a circRNA (circFCHO2)–PTBP1–GRN–NF-κB axis driving airway remodeling and showed therapeutic reversal in vivo; and a large prospective cohort with deep-learning HRCT quantification clarified progression phenotypes and risk factors in idiopathic inflammatory myopathy–associated ILD.
Research Themes
- AI-driven spatial phenomics for lung cancer risk stratification
- Non-coding RNA mechanisms driving COPD airway remodeling
- Deep-learning HRCT biomarkers for progression in myositis-associated ILD
Selected Articles
1. AI-powered spatial cell phenomics enhances risk stratification in non-small cell lung cancer.
Using histology, multiplex immunofluorescence, and multimodal machine learning across 1,168 NSCLC patients, the model identified spatial immune cell niches associated with survival. Combining niche patterns with conventional staging improved risk stratification by 14% in lung adenocarcinoma and 47% in squamous cell carcinoma, flagging undertreated high-risk patients who may benefit from adjuvant therapy.
Impact: This establishes an interpretable AI spatial phenomics pipeline that adds prognostic value beyond TNM staging in large real-world NSCLC cohorts.
Clinical Implications: Pathology workflows could incorporate multiplex imaging and AI-derived niche signatures to refine adjuvant therapy decisions and identify high-risk patients missed by conventional staging.
Key Findings
- Developed AI spatial cellomics integrating histology, multiplex immunofluorescence, and multimodal machine learning in 1,168 NSCLC cases.
- Identified survival-associated cell niches; adding niche patterns to staging improved risk stratification by 14% (adenocarcinoma) and 47% (squamous cell carcinoma).
- Revealed potentially undertreated high-risk subgroups that may benefit from adjuvant therapy.
Methodological Strengths
- Large, real-world, multicenter cohort with two independent German cancer centers
- Multimodal integration with interpretable niche-level features beyond conventional staging
Limitations
- Retrospective design limits causal inference and may introduce selection bias
- Generalizability outside the study centers and to non-European populations remains to be tested
Future Directions: Prospective trials embedding spatial niche biomarkers into adjuvant therapy decision-making and integration with genomic and circulating biomarkers to build comprehensive prognostic models.
Risk stratification remains a critical challenge in non-small cell lung cancer patients for optimal therapy selection. In this study, we develop an artificial intelligence-powered spatial cellomics approach that combines histology, multiplex immunofluorescence imaging and multimodal machine learning to characterize the complex cellular relationships of 43 cell phenotypes in the tumor microenvironment in a real-world retrospective cohort of 1168 non-small cell lung cancer patients from two large German cancer centers. The model identifies cell niches associated with survival and achieves a 14% and 47% improvement in risk stratification in the two main non-small cell lung cancer subtypes, lung adenocarcinoma and squamous cell carcinoma, respectively, combining niche patterns with conventional cancer staging. Our results show that complex immune cell niche patterns identify potentially undertreated high-risk patients qualifying for adjuvant therapy. Our approach highlights the potential of artificial intelligence powered multiplex imaging analyses to better understand the contribution of the tumor microenvironment to cancer progression and to improve risk stratification and treatment selection in non-small cell lung cancer.
2. Circular RNA FCHO2 promotes airway remodeling in COPD via regulating nuclear translocation of PTBP1 to repress the splicing of GRN pre-mRNA.
circFCHO2 is upregulated in COPD models and human lungs, drives EMT and ECM remodeling by promoting PTBP1 nuclear translocation, repressing GRN pre-mRNA splicing, reducing PGRN, and activating NF-κB signaling. In vivo knockdown of circFCHO2 mitigated cigarette smoke–induced emphysema and airway remodeling.
Impact: It reveals a novel circRNA–RNA-binding protein axis controlling airway remodeling in COPD and demonstrates functional reversal in an in vivo model, nominating tractable targets.
Clinical Implications: Targeting circFCHO2, PTBP1 nuclear translocation, or restoring PGRN/NF-κB balance could offer new anti-remodeling strategies in COPD beyond bronchodilation.
Key Findings
- circFCHO2 is significantly upregulated in COPD cell and mouse models and in human COPD lung tissues.
- Mechanism: circFCHO2 binds PTBP1, promotes its nuclear translocation, represses GRN pre-mRNA splicing, lowers PGRN, and activates NF-κB, driving EMT/ECM remodeling.
- In vivo circFCHO2 knockdown attenuates cigarette smoke–induced emphysema and airway remodeling.
Methodological Strengths
- Multi-system validation across human tissues, in vitro epithelial models, and in vivo mouse models
- Mechanistic dissection including protein interaction/localization and pathway readouts
Limitations
- Translational relevance requires human interventional validation; effects on broader COPD phenotypes remain to be tested
- Quantitative sample sizes for human tissues and potential circRNA network off-targets are not fully delineated
Future Directions: Develop antisense oligonucleotides or small molecules modulating circFCHO2/PTBP1 interactions; evaluate biomarker potential of circFCHO2 in longitudinal COPD cohorts.
Circular RNAs (circRNAs) have emerged as key regulators in human diseases, yet their mechanisms of action in chronic obstructive pulmonary disease (COPD) remain largely unknown. In this study, the conserved mammalian circRNA circFCHO2 was shown to play critical roles in COPD. The expression level of circFCHO2 was significantly increased in COPD cell models, mouse models, and human lung tissue samples. Moreover, we demonstrated that circFCHO2 promotes epithelial‒mesenchymal transition (EMT) in bronchial epithelial cells and extracellular matrix (ECM) remodeling. Mechanistically, circFCHO2 binds to and facilitates the nuclear translocation of PTBP1, thereby inhibiting the splicing of GRN pre-mRNA, which reduces PGRN protein expression levels and activates the NF-κB pathway. This activation of the NF-κB signaling pathway regulates the expression of EMT and ECM remodeling-related proteins, leading to the occurrence of airway remodeling. circFCHO2 knockdown reverses cigarette smoke-induced emphysema and airway remodeling of COPD in mice. Overall, our study advanced the understanding of the molecular mechanisms by which circRNAs contribute to airway remodeling in COPD patients.
3. Longitudinal change of idiopathic inflammatory myopathy-associated interstitial lung disease on high-resolution computed tomography, a prospective cohort study.
In a 514-patient prospective cohort, deep-learning HRCT quantification linked anti-MDA5 positivity, reduced FVC, and extensive GGO/reticulation to rapidly progressive IIM-ILD. MDA5+ dermatomyositis exhibited greater early fibrotic/inflammatory/emphysema progression and later chronic fibrosis, whereas anti-synthetase syndrome showed overall improvement.
Impact: Provides quantitative imaging biomarkers and phenotypic trajectories in IIM-ILD, enabling earlier identification of rapidly progressive disease and informing stratified management.
Clinical Implications: Anti-MDA5 testing and deep-learning HRCT quantification of GGO/reticulation can refine risk stratification, trigger early aggressive therapy, and guide monitoring intensity in IIM-ILD.
Key Findings
- Anti-MDA5 positivity (OR 10.46), reduced FVC (OR 0.91), and extensive GGO (OR 1.07)/reticulation (OR 1.23) independently predicted rapidly progressive IIM-ILD.
- During rapid progression, MDA5+ dermatomyositis had greater increases in fibrotic, inflammatory, and emphysema lesions than anti-synthetase syndrome.
- Longitudinally, MDA5+ DM trended toward chronic fibrosis, while ASS showed overall improvement; non-RP-ILD patients had much smaller lesion increases.
Methodological Strengths
- Large prospective cohort with standardized HRCT acquisition and deep-learning quantification
- Integration of imaging metrics with pulmonary function and serology for robust risk modeling
Limitations
- Single-country cohort; external validation in diverse populations is needed
- Details of algorithm generalizability and clinical decision thresholds require prospective testing
Future Directions: Prospective interventional studies using imaging-driven stratification to tailor immunomodulatory/antifibrotic therapy; external validation of deep-learning tools.
BACKGROUND: This study aimed to investigate longitudinal change of idiopathic inflammatory myopathy-associated interstitial lung disease (IIM-ILD) on high-resolution computed tomography (HRCT). METHODS: This prospective cohort study was undertaken involving 514 IIM-ILD patients (367 females; median age 54 years) from 2016 to 2022. Deep learning algorithms were employed to quantify interstitial lesions on HRCT, while clinical parameters including pulmonary function tests, serum biomarkers, and arterial blood gas analysis were also considered. RESULTS: The study identified anti-MDA5 antibody positivity (OR: 10.46, 95% CI: 3.40-32.22), reduced FVC (OR: 0.91, 95% CI: 0.84-0.98), and extensive ground-glass opacity (GGO) (OR: 1.07, 95% CI: 1.01-1.13)/ reticulation (OR: 1.23, 95% CI: 1.07-1.41) involvement as independent risk factors for rapidly progressive interstitial lung disease (RP-ILD) within IIM. During the rapid progressive period of RP-ILD, anti-MDA5-positive dermatomyositis (MDA5 + DM) showed greater progression in fibrotic, inflammatory, and emphysema lesions compared to anti-synthetase syndrome (ASS). In the slow progressive period, MDA5 + DM tended towards chronic fibrosis, while ASS exhibited overall improvement. The extent of lesion increase in non-RP-ILD patients is significantly smaller than in those who have experienced RP. Reticular and consolidation changes were strongly correlated with variations in VC%, FVC%, and FEV CONCLUSIONS: IIM-ILD cases with prior rapid progression will develop chronic fibrotic trajectories with persistent inflammation compared to non-progressive cases. ASS is characterized by sustained inflammatory activity in imaging manifestations, whereas MDA5 + DM shows post-acute fibrotic remodeling following initial injury. Longitudinal GGO emerges as a critical prognostic indicator, demonstrating time-dependent cumulative risk effects.